GlassScriptPhysician profile
Steven I Wener
NPI 1114970084
$7,495.19
in general payments reported to CMS, 2019-2025
36 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,542 · 2020: $199 · 2021: $37.07 · 2022: $1,458 · 2023: $1,373 · 2024: $1,502 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,259.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,254.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $860.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $859.33 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $520.08 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.19 | 2019-2025 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $299.78 | 2019-2025 | |
| Astellas Pharma US INC | $277.60 | 2019-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $251.72 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $215.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $178.83 | 2022-2025 | Shingrix, Arexvy |
| Abbvie INC. | $169.23 | 2019-2025 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $145.51 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $135.55 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $110.35 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $97.99 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $89.66 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.64 | 2022 | |
| Daiichi Sankyo INC. | $68.06 | 2024-2025 | Injectafer |
| Xeris Pharmaceuticals, INC. | $62.93 | 2022-2024 | Gvoke Hypopen, Keveyis |
| Janssen Pharmaceuticals, INC | $60.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.23 | 2022 | |
| Corcept Therapeutics | $49.18 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $47.26 | 2025 | Bard Urinary Drainage Bag |
| Seqirus USA INC | $45.87 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Genentech USA, INC. | $28.94 | 2019 | |
| Allergan, INC. | $26.76 | 2019 | |
| Merck Sharp & Dohme LLC | $25.57 | 2019-2024 | Capvaxive |
| Heartflow, INC. | $24.16 | 2024 | |
| Travere Therapeutics, INC. | $19.78 | 2023 | |
| Edwards Lifesciences Corporation | $19.30 | 2023 | Sapien 3 Ultra Resilia |
| Hologic Sales and Service, LLC | $17.63 | 2019 | |
| Averitas Pharma INC. | $15.98 | 2023 | Qutenza |
| Currax Pharmaceuticals LLC | $15.93 | 2022 | |
| Exact Sciences Corporation | $15.10 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $13.01 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Wener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.